CareCloud to Announce First Quarter 2025 Results on May 6, 2025
SOMERSET, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, will release its financial results for the first quarter ended March 31, 2025 before the market opens on Tuesday, May 6, 2025. The Company will follow with a conference call for investors at 8:30 a.m. Eastern Time.
The live webcast of the conference call and related presentation slides can be accessed at ir.carecloud.com/events. An audio-only option is available by dialing 201-389-0920 and referencing 'CareCloud First Quarter 2025 Results Conference Call.' Investors who opt for audio-only will need to download the related slides at ir.carecloud.com/events.
A replay of the conference call and related presentation slides will be available approximately three hours after conclusion of the call at the same link. An audio-only option can also be accessed by dialing 412-317-6671 and providing the access code 13753440.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of AI and technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at carecloud.com.
Follow CareCloud on LinkedIn, X and Facebook.
For additional information, please visit our website at carecloud.com. To listen to video presentations by CareCloud's management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.
SOURCE CareCloud
Company Contact:Norman RothInterim Chief Financial Officer and Corporate ControllerCareCloud, Inc.nroth@carecloud.com
Investor Contact:Stephen SnyderCo-Chief Executive OfficerCareCloud, Inc.ir@carecloud.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Gene Therapy Collaboration and Licensing Deals Report and Directory 2025: Explore the Financials Behind 787 Gene Therapy Licensing Deals from 2016-2025
The Gene Therapy Collaboration and Licencing Deals report features 787 deals with financial terms and SEC contracts. Explore trends in R&D partnerships, commercialization strategies, and IP structures. Ideal for benchmarking deal terms, assessing opportunities, and streamlining due diligence in the gene therapy space. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" report has been added to report contains a comprehensive listing of 787 gene therapy deals announced since 2016, including financial terms where available, and links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma revised and updated, the report provides details of gene therapy deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research and licensing initial chapters of this report provide an orientation of gene therapy dealmaking. Chapter 1 introduces the report, while Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016. Chapter 3 offers a summary of the leading gene therapy deals since 2016, listed by headline value. Chapter 4 lists the top 25 most active companies in gene therapy dealmaking, with summaries and comprehensive listings of deals. Chapter 5 and Chapter 6 offer detailed reviews of gene therapy deals and partnering deals announced since Jan 2016, focusing on contract documents in the public domain and specific gene therapy technologies report also includes numerous tables and figures that illustrate the trends and activities in gene therapy deal making since 2016. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on Therapy Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse gene therapy collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeGene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies Therapy Collaboration and Licensing Deals includes: Trends in gene therapy dealmaking in the biopharma industry Directory of gene therapy deal records covering pharmaceutical and biotechnology The leading gene therapy deals by value Most active gene therapy licensing dealmakers Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in gene therapy dealmaking2.1. Introduction2.2. Gene therapy deals over the years2.3. Most active gene therapy dealmakers2.4. Gene therapy deals by deal type2.5. Gene therapy deals by therapy area2.6. Gene therapy deals by industry sector2.7. Deal terms for gene therapy deals2.7.1 Gene therapy deals headline values2.7.2 Gene therapy deal upfront payments2.7.3 Gene therapy deal milestone payments2.7.4 Gene therapy royalty ratesChapter 3 - Leading gene therapy deals3.1. Introduction3.2. Top gene therapy deals by valueChapter 4 - Most active gene therapy dealmakers4.1. Introduction4.2. Most active gene therapy dealmakers4.3. Most active gene therapy deals company profilesChapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directoryChapter 6 - Gene therapy dealmaking by technology typeDeal directory Deal directory - Gene therapy deals by company A-Z Deal directory - Gene therapy deals by deal type Deal directory - Gene therapy deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
35 minutes ago
- Yahoo
Monaco: at the Yacht Club, Blumorpho pushes maritime finance forward, 'No time to waste'
MONACO, June 12, 2025 (GLOBE NEWSWIRE) -- The ecological transition of the maritime and port sectors has reached a critical inflection point. In a high-level working session held at the Yacht Club de Monaco, innovation met finance to chart a clear course toward healthier oceans and sustainable infrastructure. The event, led by Blumorpho in partnership with the International Association of Port Cities (AIVP) and supported by the Prince Albert II of Monaco Foundation, brought together port authorities, financial institutions, corporations, and innovators to activate actionable financial mechanisms for the sustainable transformation of coastal urban ecosystems. Part of the momentum building toward the 'Blue Economy Finance Forum' and the UN Ocean Conference (UNOC), the initiative aims to accelerate the deployment of scalable, investable solutions in support of net-zero and biodiversity objectives. Opening the session, Bernard d'Alessandri, General Secretary of the Yacht Club de Monaco, stated: 'On behalf of our President, HSH Prince Albert II, we are pleased to welcome you to the Yacht Club de Monaco to address this key issue. We would like to congratulate the Blumorpho team for their initiative and leadership. On our side, and as part of our collective ambition, 'Monaco, Capital of Advanced Yachting', we are fully committed to advancing sustainable yachting through concrete actions, including the development of the SEA Index®, a tool to assess the carbon footprint of superyachts; and support for pioneering projects through the Monaco Energy Boat Challenge (1–5 July 2025). This commitment is more essential than ever, and we are proud to contribute to the dialogue on how to protect our Ocean.' The day unfolded through expert panels, collaborative workshops, and project showcases, with three core themes emerging: ports as platforms for systemic innovation, strategic capital for climate impact, and concrete, investment-ready projects. Port cities were highlighted as drivers of integrated innovation, connecting clean energy, biodiversity, mobility, and industrial transformation. Financially, new models are gaining traction, from blended finance and blue bonds to private equity and infrastructure debt. Flagship projects from Kribi, Riga, San Diego, Genoa, and Bordeaux showcased pathways that combine decarbonization, aquaculture, digital infrastructure, and inclusive growth. 'The real challenge is not only funding the transition, but designing collaborative and business models that align profitability with long-term climate and societal goals,' explained Géraldine Andrieux, CEO of Blumorpho. Featured case studies included Ineos Energy's integrated approach to carbon capture and storage, and Republic Bank's expanding role in green infrastructure across Caribbean ports and beyond. 'As key players in the globalisation of trade, port cities bear a large share of the responsibility for the climate change. But the richness of their ecosystem means that they are also home to some of the solutions,' said Bruno Delsalle, General Manager of AIVP. The session sets the stage for a shared roadmap to be presented at the AIVP World Conference Cities & Ports 2025, scheduled in New York this November. Tisha Marajh, Group Sustainability Officer at Republic Bank, concluded with a firm call to action: 'We don't have time to waste. We are among the most affected by climate change. Phased investments tailored to attract different kinds of financing can provide a more sustainable path forward. We also need systems to identify small upstream projects, manage ESG risks, and facilitate technology transfer. Sustainable finance is a market opportunity, and we, as financial institutions, are ready to engage, if the right conditions are in place, in Caribbeans and at global scale.' For more information:- A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
36 minutes ago
- Hamilton Spectator
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting on May 29 in Pheonix, Arizona. Dr. Backus' presentation highlighted the importance of treatment adherence as a key requirement for achieving a clinically meaningful improvement in gait disability over 14 weeks of therapy and its sustained therapeutic effect well into 6 months after the end of treatment. The study results confirm controlled and real-world clinical evidence of PoNS Therapy's long-term benefits already reported in people with balance deficit due to traumatic brain injury (TBI). 'The results from this study were received with great interest as they provide the first clinical trial evidence of the long-term therapeutic benefits of PoNS Therapy for functional rehabilitation in the MS population,' stated Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. 'We were excited to engage with both US healthcare professionals and Canadian MS specialists and offer additional insights on the body of clinical and mechanistic evidence of PoNS Therapy's effect in MS. We are encouraged by the growing recognition of the importance of PoNS' direct effect on the central nervous system and its targeted mechanism of action as well as how it correlates with a lasting and sustained effect on gait rehabilitation, especially when comparing PoNS Therapy to other interventions limited to peripheral neuromuscular or transcutaneous stimulation.' CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers and appreciated the Company's relentless effort to engage with health insurance providers, viewing it as a much-needed endeavor to expand access to PoNS Therapy to all people with MS. 'We are excited by the positive conversations had at CMSC regarding both the therapeutic impact of the data presented and the recent announcement of reimbursement from the VA and out of network commercial payers for PoNS,' stated Dane Andreeff, Helius' President and Chief Executive Officer. 'We anticipate that the increase in reimbursement coverage will significantly lower the barrier to prescribe PoNS and allow for greater access to this important therapy.' About PoNS Therapeutic Experience Program (PoNSTEP) The PoNS Therapeutic Experience Program ('PoNSTEP') is a Helius-sponsored, open-label, observational, interventional multi-center outcome research study designed to assess adherence to on-label PoNS Therapy for improvement in gait deficits for patients with multiple sclerosis ('MS') in a real-world clinical setting. The study aims to understand better the relationship between adherence to on label (100-120 minute per day) PoNS Therapy, which combines the PoNS device with physical therapy, and the therapeutic outcome on gait deficit improvement over 14 weeks of study treatment, as measured by changes in the Dynamic Gait Index (DGI) scores. PoNS Therapy is applied in a supervised clinical setting for the first two weeks (Phase 1) and, independently, at home for the remaining 12 weeks (Phase 2). The study also includes a six-month no-treatment follow-up phase aimed at establishing the durability of the therapeutic effect (Phase 3). The primary endpoint of the study is maintenance of gait improvement from the end of supervised therapy (Phase 1) to the end of unsupervised therapy (Phase 2) in relation to the subject's adherence to PoNS Therapy. The secondary endpoints are, among others, maintenance of improvement of gait and balance deficit over a 6-month timeframe and clinical global impression of change. The study was performed at six Centers of Excellence across the United States, including Neurology Center of New England in Foxboro (MA), the Shepherd Center in Atlanta (GA), Montefiore Medical Center ('Montefiore') in NY (NY), Oregon Health & Science University ('OHSU') in Portland (OR), MGH Institute of Health Professions in Boston (MA), NYU Langone Health in NY (NY), and recruited 43 MS participants with gait deficit. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit . About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS or Helius Medical Technologies, visit . Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding future presentation and uses of the PoNSTEP study results, the availability of commercial reimbursement and the uses and effectiveness of PoNS and PoNS Therapy. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or . The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip Taylor Gilmartin Group investorrelations@
